Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso Sells 1,526 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 1,526 shares of Precision BioSciences stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $10.32, for a total value of $15,748.32. Following the completion of the transaction, the chief executive officer now owns 13,772 shares in the company, valued at $142,127.04. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Precision BioSciences Price Performance

Shares of DTIL stock opened at $10.52 on Friday. The stock has a 50 day simple moving average of $12.55 and a 200-day simple moving average of $11.79. Precision BioSciences, Inc. has a 12-month low of $8.25 and a 12-month high of $27.02.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share for the quarter, missing analysts’ consensus estimates of $3.00 by ($6.35). The business had revenue of $7.04 million for the quarter, compared to analyst estimates of $28.50 million. Precision BioSciences had a negative return on equity of 204.66% and a negative net margin of 125.84%. Sell-side analysts expect that Precision BioSciences, Inc. will post -3.93 earnings per share for the current year.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Curi Wealth Management LLC lifted its stake in shares of Precision BioSciences by 42.0% in the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock valued at $116,000 after purchasing an additional 100,530 shares during the period. Tejara Capital Ltd increased its holdings in Precision BioSciences by 100.7% in the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock valued at $136,000 after buying an additional 200,000 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Precision BioSciences by 8.3% in the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock valued at $1,073,000 after buying an additional 242,425 shares in the last quarter. 37.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DTIL has been the topic of a number of analyst reports. Guggenheim initiated coverage on shares of Precision BioSciences in a research report on Tuesday. They issued a “buy” rating and a $19.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Wednesday, April 17th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.